Form 4: Jazz Pharma Director Cozadd Boosts Stake Post-Vesting

Jazz Pharmaceuticals plc Director Bruce C. Cozadd increased his direct beneficial ownership of ordinary shares following the vesting of performance awards and subsequent tax-related share withholding.

Summary

• Bruce C. Cozadd, a Director of Jazz Pharmaceuticals plc, reported changes in his beneficial ownership of ordinary shares.
• On January 16, 2026, Mr. Cozadd acquired 35,917 ordinary shares at a price of $0.0 per share, resulting from the vesting of performance share awards granted on March 3, 2023.
• The performance-based vesting requirements for these awards were satisfied and certified on January 16, 2026.
• Concurrently, 17,453 ordinary shares were disposed of at a price of $171.16 per share to satisfy tax obligations related to the vesting of these performance share awards.
• Following these transactions, Mr. Cozadd's direct beneficial ownership stands at 411,796 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the vesting of performance awards, indicating achieved targets, and a net increase in the director's beneficial ownership, which aligns insider interests with shareholders. The tax withholding is a neutral, standard event.

Positives

• The vesting of 35,917 performance share awards indicates the achievement of previously set performance targets by the company.
• A net increase in the director's direct beneficial ownership by 18,464 ordinary shares (35,917 acquired 17,453 disposed) demonstrates continued alignment of management interests with shareholders.

Future Outlook

This Form 4 filing reports past transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Form 4 filings are routine disclosures in the U.S. financial markets, reporting changes in beneficial ownership by company insiders. The vesting of performance share awards and subsequent tax withholding are standard practices for executive compensation in publicly traded companies within the pharmaceutical industry and beyond.

Stakeholder Impact

• Shareholders may view the increase in director ownership as a positive signal, indicating management's confidence in the company's future prospects and aligning their interests with long-term shareholder value.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Transaction, Beneficial Ownership, Stock Awards, Director, Equity Compensation